Ellen Snow

Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA.

AlerisLife, Inc. engages in the operation of senior living communities and rehabilitation and wellness services clinics. It operates through the Senior Living and Rehabilitation and Wellness Services segments. The Senior Living segment is involved in the operation of independent assisted living communities, skilled nursing facilities, and continuing care retirement communities. It also offers memory care living units specializing in the care of those with Alzheimer's. The Rehabilitation and Wellness Services segment provides physical, occupational, speech, and other specialized therapy services in inpatient and outpatient clinics. The company was founded by Barry Michael Portnoy and Gerard Michael Martin in April 2000 and is headquartered in Newton, MA.